Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure

Exclusion Criteria

• •Female participants who are pregnant, lactating, or of child bearing potential
• •History of type 1 or type 2 diabetes mellitus by medical history or hemoglobin A1c \>7.0% at Visit 1
• •Clinical diagnosis of HFpEF or HFrEF by participant self-report or documented in the electronic health record
• •Any LVEF measure of ≤40% on past echocardiogram
• •Moderate or severe valve disease on echocardiogram
• •History of genitourinary infection
• •eGFR \<60 ml/min/1.73 m2 at Visit 1
• •Current treatment with SGLT2 inhibitor, GLP1 agonist, or DPP4 inhibitors
• •Participants in whom coronary revascularization by either PCI or bypass surgery is being contemplated within 6 months, or who have undergone revascularization in the prior 2 months
• •Significant allergy or known intolerance to SGLT2 inhibitors or any ingredient in the formulations
• •Participants currently experiencing any clinically significant or unstable medical condition that might limit their ability to complete the study, or to comply with the requirements of the protocol, including: dermatologic disease, hematological disease, pulmonary disease, hepatic disease, gastrointestinal disease, genitourinary disease, endocrine disease, neurological disease, and psychiatric disease
• •Any malignancy not considered cured (except basal cell carcinoma of the skin). A participant is considered cured if there has been no evidence of cancer recurrence for the 5 years prior to screening
• •Participants who have participated in studies of an investigational drug or device within 30 days prior to the screening visit
• •Inadequate quality echocardiographic images
• •Unstable coronary syndromes
• •Major surgery (major according to the investigator's assessment) performed within 90 days prior to Visit 1 or scheduled major elective surgery within 90 days after Visit 1.
• •Non-English speaking individuals